Sotyktu (deucravacitinib)

Sotyktu (deucravacitinib) for sale – Buy Sotyktu (deucravacitinib) online

What is Sotyktu (deucravacitinib) for?

Sotyktu (deucravacitinib) is an allosteric tyrosine kinase 2 (TYK2) inhibitor, for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Sotyktu is not recommended for use in combination with other potent immunosuppressants. Sotyktu works to treat psoriasis by inhibiting TYK2, an intracellular signaling kinase that mediates signaling of IL-23, IL-12 and Type I IFN, which are naturally occurring cytokines involved in inflammatory and immune responses.

Where has Sotyktu (deucravacitinib) been approved?

Sotyktu (deucravacitinib) was approved by the U.S. Food and Drug Administration (FDA) in September 2022.

The prescribing information for Sotyktu can be consulted here.